- Home
- SJT vs CHRS Comparison
SJT vs CHRS Comparison
Compare SJT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- CHRS
- Stock Information
- Founded
- SJT 1980
- CHRS 2010
- Country
- SJT United States
- CHRS United States
- Employees
- SJT N/A
- CHRS N/A
- Industry
- SJT Oil & Gas Production
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SJT Energy
- CHRS Health Care
- Exchange
- SJT Nasdaq
- CHRS Nasdaq
- Market Cap
- SJT 281.5M
- CHRS 84.2M
- IPO Year
- SJT N/A
- CHRS 2014
- Fundamental
- Price
- SJT $6.20
- CHRS $0.83
- Analyst Decision
- SJT
- CHRS Buy
- Analyst Count
- SJT 0
- CHRS 3
- Target Price
- SJT N/A
- CHRS $4.68
- AVG Volume (30 Days)
- SJT 238.4K
- CHRS 1.3M
- Earning Date
- SJT 08-13-2025
- CHRS 08-07-2025
- Dividend Yield
- SJT N/A
- CHRS N/A
- EPS Growth
- SJT N/A
- CHRS N/A
- EPS
- SJT 0.02
- CHRS N/A
- Revenue
- SJT $1,931,777.00
- CHRS $272,251,000.00
- Revenue This Year
- SJT N/A
- CHRS N/A
- Revenue Next Year
- SJT N/A
- CHRS $106.56
- P/E Ratio
- SJT $265.48
- CHRS N/A
- Revenue Growth
- SJT N/A
- CHRS 19.87
- 52 Week Low
- SJT $3.21
- CHRS $0.66
- 52 Week High
- SJT $7.22
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- SJT 49.59
- CHRS 56.33
- Support Level
- SJT $6.01
- CHRS $0.73
- Resistance Level
- SJT $6.26
- CHRS $0.82
- Average True Range (ATR)
- SJT 0.27
- CHRS 0.04
- MACD
- SJT 0.01
- CHRS 0.01
- Stochastic Oscillator
- SJT 48.03
- CHRS 99.23
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.